Svensk version All offices All contacts Home About Sobi Patients Products Pipeline Partnering Healthcare Professionals Investors & Media Products Sobi has a diversified and growth-oriented commercial product portfolio within three business lines. To products Our pipeline Sobi’s pipeline programs are focused on recombinant protein drugs for specialist indications for the global market. Read more about Sobi's pipeline Annual General Meeting The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Thursday, May 8, 2014 in Wallenbergssalen at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden Read more Presentation of Sobi's Interim Report April - June 2014 18 July 2014, Sobi's Report for the second quarter 2014 was published - Revenues for the quarter totalled SEK 663 M (520), an increase of 27 per cent. To Interim Report Q2 2014 To Annual Report 2013 Financial report archive Presentation archive Share Price SEK77.80 SEK 0.40 Procent 0.52% Volume: 622,316 Ticker: SOBI List: SSE Large More About the Share News Reports Show: All News Press releases Sobi expands Haemophilia development portfolio - elects to include potentially longer-a... 2014-09-19 08:00 in Press releases New number of shares and votes in Swedish Orphan Biovitrum AB 2014-07-31 08:00 in Press releases Sobi's board of directors exercises authorisation for repurchase of shares for the purp... 2014-07-18 09:00 in Press releases Sobi publishes Report for the Second Quarter 2014 2014-07-18 08:00 in Press releases More news Contact Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden Phone: +46 8 697 20 00 Reg.No. 556038-9321 © Swedish Orphan Biovitrum AB, 2013 Quick Links Terms of use & cookies All contacts Follow us Press releases News Financial reports